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MitocanWith the arrival of the third millennium, in spite of unprecedented progress in molecular medicine, cancer
remains as untamed as ever. The complexity of tumours, dictating the potential response of cancer cells to
anti-cancer agents, has been recently highlighted in a landmark paper by Weinberg and Hanahan on hallmarks
of cancer [1]. Together with the recently published papers on the complexity of tumours in patients and even
within the same tumour (see below), the cure for this pathology seems to be an elusive goal. Indisputably, the
strategy ought to be changed, searching for targets that are generally invariant across the landscape of neoplastic
diseases. One such target appears to be themitochondrial complex II (CII) of the electron transfer chain, a recent
focus of research. We document and highlight this particularly intriguing target in this review paper and
give examples of drugs that use CII as their molecular target. This article is part of a Special Issue entitled:
Respiratory complex II: Role in cellular physiology and disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The improvement in sequencing and bioinformatic technology lead
to a realisation that tumours are heterogeneous, as exempliﬁed by recent
reports revealing the extraordinary variability of mutations in tumours
of the same type in different patients [2–4]. This grim notion has been
further accentuated by a publication documenting the differences in
mutational signatures in different regions of a single tumour and
the derived metastases, as shown for renal carcinoma patients [5].opyruvate; CI, complex I; DCA,
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l rights reserved.These ﬁndings underscore the improbable task of ﬁnding a good cancer
cure that would target only a single gene or a single signalling pathway.
This is most likely also a major reason why cancer incidence is either
stagnating or on the rise, depending on the particular type of tumour
[6–8]. Therefore, mitochondria came into the focus of contemporary re-
search of cancer biologists.
The importance of mitochondria as potential targets in cancer cells
stems from the fact that they are a reservoir of proteins that promote
the apoptotic death when mobilised into the cytosol [9,10]. This notion
and the fact thatmitochondria are functional, at least to some extent, in
most if not all cancer cells, has fuelled considerable interest in these
organelles [10–16]. Due to the intriguing nature of mitochondria and
accumulating evidence for these organelles comprising a variety of
targets for anti-tumour agents, we decided to group these agents
under the collective name of ‘mitocans’, an acronym epitomising
the terms ‘mitochondria’ and ‘cancer’ [17,18]. The classiﬁcation of
mitocans has been proposed: we deﬁned 8 classes, according to the
individual molecular targets at and inside mitochondria (Fig. 1)
[19]. Some of these agents have been trialled pre-clinically and are
undergoing clinical trials, showing promise to be developed into
clinically relevant drugs [20].
Our major interest has been focused on class 5 mitocans, i.e. agents
acting on themitochondrial electron transport chain (ETC.) [20]. The rea-
son for this has been that in our aspiration to understand the molecular
mechanism of the induction of apoptosis by the redox-silent vitamin E
(VE) analogue α-tocopheryl succinate (α-TOS), which is also a selective
anti-cancer drug as shown in pre-clinical experiments [21–25], we dis-
covered that the molecular target for the agent is the mitochondrial
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since VE analogues are likely to enter clinical trials, we believe that it is
of importance to document the role of CII as a site of the action of
anti-cancer drugs, which is the thrust of this review paper.
2. Biology of complex II
Mitochondrial complex II (CII), also known as succinate dehydroge-
nase (SDH) or succinate:ubiquinone oxidoreductase (SQR), contains
four nuclear encoded subunits: SDHA, SDHB, SDHC and SDHD (called
Sdh1–4 in yeast and SdhA–SdhD in bacteria) and, unlike other mito-
chondrial complexes, lacks subunits encoded by the mitochondrial ge-
nome. CII has a dual role, i.e. in the ETC. and the tricarboxylic acid
(TCA) cycle, linking the two essential energy-producing processes of
the cell [28–30]. In TCA cycle, SDH oxidises the metabolite succinate
to fumarate, and this reaction is inherent to the SDH activity of CII
[30]. As a component of the respiratory complex, it transfers electrons
from succinate to ubiquinone (UbQ), referred to as the SQR activity.
Bacterial fumarate reductase (also known as succinate:quinone oxido-
reductase), which has functional and structural homology to CII
[31,32], catalyses the reverse reaction of reducing fumarate to succinate
during anaerobic respiration [31,33]. The structure of CII puriﬁed from
porcine heart resolved at 2.4 Å resolution [34] revealed the head-tail ar-
rangement of the hydrophobic subunits (SDHC and SDHD) embedded
within themitochondrial innermembrane (MIM)with a short segment
extended into the intermembrane space, while the catalytic subunit
SDHA and the SDHB subunit are projected into the matrix (see Fig. 2
for CII structure and function).
In contrast to the semi-sequential assembly manner of CI [35], the
presence of all subunits of hydrophilic and hydrophobic cores is essential
for the stability of functional CII as demonstrated in yeast. Thus, yeast
lacking one of the subunits shows a low abundance of the other subunitsFig. 1. The classiﬁcation of mitocans. Mitocans, small molecules with anti-cancer activity tha
agents targeting HK, Class 2 compounds acting on Bcl-2 family proteins (BH3 mimetics and
on the VDAC and ANT channel proteins, Class 5 agents targeting the ETC., Class 7 lipophilic
Class 8 compounds acting on mtDNA. Highlighted are the Class 5 mitocans and CII, which a[36]. However, the catalytic subunits of Escherichia coli fumarate reduc-
tase are stable and partially active even in the absence of hydrophilic
subunits [37]. These ﬁndings led to the question howmammalianmito-
chondrial SDH evolved and whether it features unique assembly and
regulatory mechanisms.
To carry out its dual activity of electron transfer to UbQ and of
oxidising succinate to fumarate, prosthetic groups are required.
Accordingly, CII comprises ﬁve prosthetic groups including FAD in
the SDHA subunit, three iron–sulfur clusters ([2Fe–2S], [4Fe–4S] and
[3Fe–4S]) bound in SDHB, and heme inserted within the hydrophobic
pocket between SDHC and SDHD. Attachment of these prosthetic
groups to the individual subunits, although considered to be autocata-
lytic, has been documented to require speciﬁc proteins collectively
termed ‘assembly factors’ that assist the insertion of prosthetic groups
into the holo-form of subunits. Studies on the biogenesis of CI indicated
that it requires more than 9 assembly factors [35,38]. Similarly, numer-
ous factors are also required for the assembly of CIII, CIV and CV. On the
other hand, the assembly ofmammalian CII is not known inmuch detail
and thus far only two assembly factor proteins have been identiﬁed.
SDH assembly factor-1 (SDHAF1) is required for the insertion of iron–
sulfur clusters in SDHB [39] and SDHAF2, also known as SDH5, for the
ﬂavination of SDHA [36].
SDHAF1 belongs to the LYR family of proteins that contain the
conserved LYR (LYK) tripeptide motif in the N-terminal region,
which is a typical signature of proteins involved in iron–sulfur cluster
metabolism. Analogously, other LYR protein family members localise
to mitochondria, such as NDUFA6 and NDUFB9 of CI. This implicates a
role for the iron–sulfur cluster formation in CI, while the yeast Mzm1
protein assists the assembly of the Rieske iron–sulfur protein Rip1 in
CIII [40]. Molecular details of the role of SDHAF1 in the insertion of
iron–sulfur clusters in the SDHC subunit, which is associated with
CII assembly, however, remain to be determined.t act upon mitochondria, are classiﬁed into several classes. Class 1 mitocans comprises
similar compounds), Class 3 and 4 compouds with redox-inhibitory function and acting
compounds targeting the inner membrane, Class 7 agents targeting the TCA cycle, and
s a target for anti-cancer drugs is the subject of this paper. Adapted from [19].
Fig. 2. The structure of complex II. Complex II consists of four subunits, the 70 kDa
SDHA (Fp), the 30 kDa SDHB (Ip), the 15 kDa SDHC (CybL) and the 13 kDa SDHD
(CybS) subunit. The SDHA subunit contains the prosthetic group FAD, which partici-
pates in the TCA cycle, converting succinate to fumarate (SDH activity of CII), resulting
in the generation of FADH2 that feeds electrons to CII. The two electrons generated
from conversion of succinate to fumarate are mobilised to the SDHB subunit that com-
prises three [Fe–S] clusters arranged to force the movement of electrons to the mem-
brane ‘portion’ of CII composed of the SDHC and SDHD subunits with the heme and
UbQ prosthetic groups. Heme helps stabilise electrons adjacent to UbQ to help with
the two-electron reduction of UbQ to UbQH2 (SQR activity of CII). UbQH2 then leaves
its site in CII to transverse to CIII, where it is re-oxidised, returning to CII. Shown are
also two assembly factors, SDHAF2 (SDH5) helping insert FAD into SDHA, and
SDHAF1 with a role in the insertion of the [Fe–S] clusters into the SDHB subunit.
Adapted from [19].
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unannotated mitochondria proteins [36,41]. Subsequent sequence
analyses have suggested that SDH5 is not a bona ﬁde member of any
superfamily and is not homologous with any known domain or motif;
it is now assigned its own speciﬁc group called ‘SDH5 superfamily’. It
has been shown that SDH5 physically associates with SDHA and that it
is essential for incorporation of FAD to form the active SDHA ﬂavopro-
tein. The molecular mechanism of SDH5-assisted insertion of FAD to
SDHA is still to be completely resolved in eukaryotes, while recent stud-
ies using a homologous bacterial protein SdhE revealed that SdhE itself
directly binds FAD via a covalent chemical interaction [42]. It is likely
that SdhE acquires FAD from the aqueous environment and hands it
over to SdhA. Similarly as for eukaryotes, the mechanism of FAD
mobilisation from SdhE to SdhA is not precisely known, and neither is
it known whether other macromolecules are involved in the ﬂavination
of SdhA. In yeast mitochondria, the ﬂavin transporter Flx1 [43] and the
‘chaperone-like’ Tcm62 protein [44] have also been reported as assembly
factors of CII, although it is not clear yet whether they play a broader role
inmitochondria or are dedicated solely to the assembly process [45–47].
Additional modiﬁcation of CII was proposed on the post-translational
level that couldmodulate its activity. Proteome-wide screen showed that
SDHA features 13 acetylated lysine residues [48], which lead to the prop-
osition that deacetylation of these residues by SIRT3 might modulate the
SDH activity of CII in a tissue-dependentmanner [48,49]. Also, in vitro ex-
periments revealed that the Fgr tyrosine kinase phosphorylates two Tyr
residues (Y535 and Y596) of SDHA [50], although the physiological
signiﬁcance of this post translational modiﬁcation remains unclear.
Additional experiments are needed to better understand the precise
molecular mechanism of the assembly and modiﬁcations of the sub-
units of CII in order to comprehend the importance of the role of CIIat the ‘crossroads’ of the TCA cycle and the ETC. The importance of
the assembly factors in the function of CII is accentuated by their re-
cently discovered role as tumour suppressors [36,39].
3. The role of complex II in mitochondrial bioenergetics and
mutagenesis
With respect to CII as a target for anti-cancer drugs, it is useful to
note that CII subunits function as tumour suppressors. Genes coding
for complex II (CII) subunits have received considerable attention in
the context of cancer susceptibility genes since 2000, when ﬁrst
germline mutations in SDHD and SDHC were reported in families
with hereditary paraganglioma (PGL) [51,52]. Very soon familial
pheochromocytoma (PHEO) revealed SDHD germline mutations
[53], and in the same year these authors found germline SDHB muta-
tions in both familial diseases [54]. Finally, very recently a mutation in
the SDHA subunit was identiﬁed in a PGL patient [55]. The role of CII
in PGL was further strengthened by the ﬁnding that the CII assembly
factor SDH5 was also marked as a tumour susceptibility gene [36]. In
addition, mutations in several other genes have been found to be as-
sociated with this syndrome [56]. More on SDHmutations and associ-
ated cancers can be found in a recent review by Bardella, Pollard and
Tomlinson [57] and elsewhere in this issue.
It is not yet entirely clear why CII deﬁciency gives rise to cancer. It
has been reported that the activity of CII in tumours bearing SDHA-D
mutations is compromised [58–61]. As CII converts succinate to fuma-
rate in the TCA cycle, this results in succinate accumulation and sub-
strate inhibition of prolyl hydroxylase enzymes (PHDs), which also
form succinate as an end product. PHDs play an important regulatory
role, as they hydroxylate hypoxia-inducible factors (HIF1 and HIF2)
and in this way mark them for proteasomal degradation [62]. When
HIFs are present, they activate transcription of various genes implicated
in cancer like glucose transporters, enzymes promoting glycolysis and
the pro-angiogenic vascular endothelial growth factor. Indeed, HIF
protein stabilisation has now been demonstrated in a number of CII
deﬁcient tumours [59,60,63]. In addition, it has been shown in a yeast
model of SDHB deﬁciency that increased succinate levels may inhibit
histone demethylases [64]. Similarly to isocitrate dehydrogenase muta-
tions [65], it was subsequently demonstrated that CIImutationsmay re-
sult in altered epigenetics in mammalian cells [66], but this has as yet
not been shown for human cancers.
The accumulation of succinate is undoubtedly an important feature
of CII-deﬁcient cancers, but the ‘succinate theory’ cannot explain all
of the clinical observations. For example, the deﬁciency in the SDHA
subunit should result in massive succinate accumulation as SDHA con-
tains the catalytic site responsible for the succinate to fumarate conver-
sion, yet SDH-deﬁcient tumours are extremely rare, while mutations in
SDHB-D are much more common. SDHA was in fact not considered a
tumour suppressor until 2010 when heterozygous mutation was
identiﬁed in a catecholamine-secreting abdominal paraganglioma
[55]. An alternative theory has been proposed, suggesting reactive
oxygen species (ROS) as culprits of increased tumourigenesis. CII
has been shown to be a site of ROS generation (references [67,68]
and Moreno-Sanchez et al., submitted for publication), and in
SDHA-deﬁciency there could be no ROS produced from CII due to the ab-
sence of electron ﬂow from the non-existent active site, which is consis-
tent with the limited occurrence of SDHA tumours. Increased ROS may
result in HIF1 accumulation, but also in increased DNA mutational rate
and tumourigenesis [69–71]. However, various groups using various
models have reported either increased or normal levels of ROS in CII de-
ﬁcient cells, and this issue remains to be resolved [69,70,72,73]. Increased
ROS have not been detected in SDHB-deﬁcient tumours, but the tumour
tissue featured elevated superoxide dismutase expression, suggesting
that the cells could have adapted to an increase in ROS production over
time [61]. It is possible that the individual factors (such as succinate accu-
mulation and ROS production) may be of varying importance based on
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subunit that is absent or harbours the tumour-associated
mutation(s).
Clinical manifestation of cancer differs, depending on which one of
the CII subunits is defective. In PGL/PHEO, the most aggressive tumours
are those deﬁcient or malfunctional in SDHB due to their highmetastatic
potential; they are generally diagnosed at younger age [74,75]. In
contrast, SDHD-deﬁcient tumours give rise to metastasis only very
infrequently, and SDHC-deﬁcient tumours even less so, while
SDHA-derived tumours are extremely rare. SDHB tumours are rela-
tively frequent in sporadic cases, while SDHC and SDHD tumours
are mostly hereditary [75]. This appears an enigma, as ‘SDHC/SDHD
cases’ often involve a complete loss of the subunit, which then re-
sults in the absence of SDHB as well (probably due to the failure to
properly assemble CII), and one would therefore expect that the
manifestation will be the same or not too dissimilar. It was even
suggested that the absence of SDHB in PGL/PHEO biopsies could be
a surrogate marker for the presence of mutations in SDHB, SDHC or
SDHD [76]. To our knowledge, these differences remain unexplained,
and no rigorous biochemical examination has been performed to
compare SDHB and SDHC/SDHD tumours or in vitro models. However,
a possibility exists that these differences derive from the chromosomal
location of individual SDHgenes. For the development of PGL/PHEO, the
second allele of the particular SDH gene harbouring the germlinemuta-
tion is usually inactivated, and this may result in the concomitant elim-
ination of additional tumour suppressor genes in the vicinity of the loci
during somatic loss of the second allele [75].
Based on the twomechanisms proposed to be responsible for tumour
formation, α-ketoglutarate derivatives and antioxidants were proffered
as a therapy, or as a prevention in individuals with familial history of CII
mutations. Cell permeable α-ketoglutarate derivatives, substrates for
PHD enzymes, were shown to restore the PHD activity in CII-deﬁcient
cells, relieve pseudohypoxia [77] and reverse the hypoxia-mediated
HIF1α stabilisation with decrease in glycolysis and ensuing cell death in
a xenograft tumour model [78]. A lipid soluble antioxidant, vitamin E,
protected cells with CII mutations from oxidative damage represented
by lipid peroxidation and reversed their phenotype characterised by ap-
optosis resistance [79].
Since CII may serve as a target for anti-cancer agents, it is necessary
to realise that CII deﬁciency is present only in the minority of cancers,
and even though CII-deﬁcient cells display lower response to CII-
targeted agents such asα-TOS/MitoVES [27,80], this should not present
a substantial problem overall. In addition, despite the typical pro-
glycolytic changes in many cancer cells, the oxidative phosphorylation
(OXPHOS) in large majority of cancer cells is present, albeit often atten-
uated. This may stem from the fact that in most cancers the glycolytic
pathway may be required to supply necessary building blocks for
biosynthetic pathways, and not from the necessity to supply the
cell with ATP, and cancer cells still mostly have functional OXPHOS
[81–84]. Therefore, in most cancers, components of OXPHOS are a
suitable target not only for CII-directed agents, but also for other
compounds that kill cancer cells by targeting the other respiratory
complexes [20]. In addition, it could be perhaps possible to pharma-
cologically manipulate a cancer cell in such a way that it would be
‘primed’ for CII-targeted therapy. For example, Pistollato and col-
leagues reported that the glucose analogue 2-deoxyglucose, which
inhibits hexokinase, the ﬁrst enzyme of the glycolytic pathway,
caused an increase in the SDH activity of CII and decreased succinate
levels in glioblastoma multiforme cells [85]. It is important to bear in
mind, though, that acute inhibition of glycolysis would reduce
OXPHOS as well, because the end product of glycolysis, pyruvate,
would be less abundant and hence there would be less ‘fuel’ for the TCA
cycle to produce the NADH and FADH2 for respiration. A plausible ap-
proach is to re-direct the metabolite ﬂow of cancer cells to mitochondria
using dichloroacetate (DCA), which inhibits the key enzyme regulating
the fate of pyruvate, pyruvate dehydrogenase kinase (PDK) and is alreadyused in the clinic to treat lactic acidosis [86]. PDK is overexpressed in
cancer cells and phosphorylates and inhibits pyruvate dehydrogenase,
so that the end product of glycolysis, pyruvate, cannot enter the mito-
chondrial TCA cycle and is instead converted to lactate in the cytoplasm.
Using DCA, glycolysis could still supply pyruvate to maintain the elec-
tron ﬂow through OXPHOS, and further with the inhibition of lactate
production by lactate dehydrogenase [87] the redox balance would be
impaired and the cell would be more vulnerable to the oxidative stress
induced by CII targeting.
4. Complex II as a target for anti-cancer agents
4.1. General aspects
CII, the smallest of the respiratory complexes [34,88], has recently
attracted considerable attention, one reason being since it is at the
branching point connecting the TCA cycle and the ETC. While other
complexes of the respiratory chain contribute to the maintenance of
the proton gradient across the MIM, CII lacks this activity. It can be
postulated that the major role of CII is to drive the TCA cycle in the
‘clockwise’ direction by the conversion of succinate to fumarate, i.e. in
the direction whereby generating NADH, feeding into CI. The electrons
released from the conversion succinate to fumarate are then mobilised
to the UbQmolecule bound in themembrane ‘portion’ of CII, causing its
reduction to UbQH2. Further, UbQ in its reduced form relaxes its associ-
ation with CII and donates the two electrons to CIII, where it causes re-
duction of CIII's UbQ, itself being re-oxidised. Due to its increased afﬁnity
for its CII site, it re-associates with its natural binding domain. Thus, the
diversion of electrons from the CII's FAD keeps the SDH activity at the op-
timum rate.
The crystal structure of CII of both prokaryotes (E. coli) and eukaryotes
(porcine complex) has been resolved, which gave us a detailed and rea-
sonably precise understanding of its structure and its potential functional
consequences [31,34]. This alsomade itmore feasible to design strategies
of targeting CII for apoptosis induction in cancer cells. Apart from papers
studying agents that bind to various sites of CII and are considered excel-
lent molecular tools rather than potential anti-cancer agents, the ﬁrst re-
port, to the best of our knowledge, indicating that CII plays a role in
apoptosis, was published by Albayrak and colleagues [89]. In this paper
the authors reported on efﬁcient apoptosis in parental cells and its
suppression upon mutation in one of the CII subunits (SDHC). The
triggers usedwere both small pharmacological agents aswell as ligands
activating the death receptors, as exempliﬁed by the Fas ligand. This
breadth of inducers suggested that CII is not an actual target for all
these agents but, rather, a mediator of, probably, the earlier stages of
the apoptotic process. This is in particular true for apoptosis induced
via activation of the death receptors.
4.2. Vitamin E analogues
Wehave been studying for some time themolecular mechanism and
the anti-oxidant properties of a redox-silent VE analogue α-TOS
(Table 1). This agent is of considerable interest, since it is derived from
the nutritionally essential α-tocopherol but, unlike its redox-active
counterpart, lacks the anti-oxidant activity and suppresses cancer
in animal models [21,90]. A particularly intriguing feature of α-TOS
is its selectivity for cancer cells [91]. The potential importance of
α-TOS stems from ﬁndings that it is efﬁcient, without secondary toxicity,
against a number of experimental cancers, including colon, breast, pros-
tate and lung cancer, as well asmesotheliomas andmelanomas, to name
only a few [21,22,24,92–97]. A variant of α-TOS, α-tocopheryloxyacetic
acid (α-TEA),was shown to suppress ovarian and breast cancer in exper-
imental animals [98,99].We found that the etherα-TEA ismore efﬁcient
in suppressing spontaneous breast carcinomas in the transgenic FVB/N
c-neu mice due to its longer half-life in vivo compared to the ester
α-TOS [100].
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tion of ROS, with ensuing formation of a Bax or Bak pore in the mito-
chondrial outer membrane (MOM) [17,21,23,101]. We found that
addition of radical scavengers, such as α-tocopherol, suppressed ROS
generation and apoptosis induction [21]. The radical species formed is
most likely superoxide that then promotes apoptosis. It has been
proposed that this can occur either in a transcription-independent
manner via Bax dimerisation and its insertion into the MOM or tran-
scriptionally via Noxa upregulation and formation of a Bak channel
in the MOM [17] (see below).
More detailed analysis identiﬁed that, at least in some types of cancer
cells (as shown for Jurkat T lymphoma and non-small cell lung carcinoma
cells), following the initial ROS generation in response ofα-TOS stimula-
tion, the Mst1 kinase is activated, phosphorylating and activating the
transcription factor FoxO1. This results in transcriptional upregulation
of the Bcl-2 homology-3 (BH3)-only protein Noxa [25]. Noxa then diverts
the anti-apoptotic proteinMcl-1 fromBak,which is free to forma channel
in the MOM [102]. ROS dependent mobilisation of Bax to the MOM has
also been proposed [17,23,101].
Shiau et al. [103] reported that α-TOS and its analogues have the
propensity to interact with the BH3 domains of Bcl-2 and Bcl-xL,
whereby inhibiting their anti-apoptotic function. This may be a reason
whyα-TOS and its analogues have been shown to synergisewith several
anti-cancer agents, including TRAIL [27,104], paclitaxel [105], cisplatin
[106], or tamoxifen [107]. The notion that α-TOS interacts with BH3
domains of Bcl-2 family of proteins places the agent and its analogues
to Class 2 of mitocans [19] (Fig. 1). However, the fact that cancer cells
respond to the agent by rapid ROS generation [23,108–111] indicates
that α-TOS targets a particular site in mitochondria that results in ROS
formation. Such a target has been proposed for α-TOS to be the mito-
chondrial CI, although the precise mechanism for the interaction with
this multicomponent respiratory complex has not been documented
[111].
Our attempt to ﬁnd the molecular target for α-TOS resulted in the
identiﬁcation of CII as the species via which the VE analogue interacts
to induce apoptosis in cancer cells [26]. This was shown initially using
biochemical methods, which allowed us to suggest the UbQ site(s) in
CII as the target for α-TOS, rather than the FAD site in its SDHA
subunit. Molecular modelling indicated strong interaction of α-TOS
with both the proximal (Qp) and the distal UbQ site (Qd) [34] of CII
[26]. More speciﬁcally, α-TOS was found to have a strong hydrogenTable 1
Compounds targeting complex II.
Compound Structure
α-Tocopheryl succinate (α-TOS)
Mitochondrially targeted vitamin E succinate
(MitoVES)
3-Bromopyruvate (3BP) BrCH2-CH2-COOH
Malonate
Nitropropionic acid (3NP) O2N-CH2-COOH
Thenoyltriﬂuoroacetone (TTFA)
Troglitazone
Atpenin A5bond with the ubiquinone-binding Ser68 of Qp in the SDHA subunit
(Fig. 3A,B) and with SDHD's Lys128/135 [26] of the less well
characterised Qd [34]. The notion that CII is a target forα-TOS was cor-
roborated by loss of apoptosis and ROS generation in cells with a muta-
tion causing a loss of the SDHC subunit, which was overcome by
reconstitution of the functional complex [26]. Importantly, too, tumours
derived from CII-compromised H-Ras-transformed Chinese hamster
lung ﬁbroblasts were resistant, while the tumours derived from
CII-competent (either parental or reconstituted) cells were suscepti-
ble to α-TOS treatment [27] (Fig. 3C–E). These ﬁndings clearly
document CII as a novel target for compounds with a clinical
potential, epitomised by the promising α-TOS. Consistent with
this, we also reported that α-TOS and α-TEA selectively suppress an-
giogenesis by interacting with CII of the proliferating endothelial cells
[112].
Identiﬁcation of the target forα-TOSwithin theMIMprompted us to
develop a novel group of anti-cancer agents by tagging VE analogues
with a cationic triphenylphosphonium (TPP+) group. This reasoning
was based on the pioneering work of Murphy and Smith, who attached
the TPP+ group to a range of compounds, in particular the redox-active
UbQ to formmitochondrially targeted ubiquinone (MitoQ) as well as to
radical scavengers accumulating in mitochondria, such as MitoB and
MitoP used to evaluate the production of hydrogen peroxide inside mi-
tochondria of live cells [113–115]. The principle of targeting a hydro-
phobic agent into mitochondria by tagging it with TPP+ is based on
the fact that the delocalised charge on the quarternary phosphorus
will cause up to 1000-fold accumulation of the modiﬁed compound in
mitochondria, such that the TPP+ group will be at the matrix face
of the MIM and the bioactive, hydrophobic part (as in MitoQ) inside
the MIM [114]. We applied this principle to vitamin E succinate
(VES) to generate mitochondrially targeted VES (MitoVES) (Table 1)
[80,116].
Based on the above assumptions, we can reason that due to its
chemico-physical properties, MitoVES will span the interface of the
MIM and themitochondrial matrix with the bioactive tocopheryl succi-
nyl group in the proximity of Ser68 of the Qp site (Fig. 4A,B). For reasons
of being anchored at the interface by the TPP+ group, MitoVES will
never reach the Qd site. In other words, by tagging VES with TPP+, we
send the agent directly where it matters, i.e. to its site in the MIM, in-
creasing its concentration within the mitochondria theoretically by
the factor of 103 compared to that of the untagged parental compound.
MitoVES was found to be very efﬁcient in apoptosis induction in cancer
cells, some 20–50 more than found for α-TOS [80,116]. It triggered ap-
optosis by interaction with the CII's Qp, causing rapid generation of ROS
followed by activation of Mst1, nuclear translocation of FoxO1, in-
creased expression of the Noxa protein and generation of the Bak pore
in theMOM [80,116], essentially as found earlier forα-TOS [25,102]. In-
terestingly, too, unlike α-TOS that could induce apoptosis, albeit de-
layed, MitoVES was completely inefﬁcient in apoptosis induction in
Jurkat cells lacking both Bak and Bax proteins, a prerequisite for the for-
mation of anMOMpore [80,116]. This documents that whileα-TOS can
also destabilise other structures thanmitochondria (such as lysosomes)
[117,118], MitoVES is mitochondria-speciﬁc due to its localisation
(Fig. 4A, B).
The molecular target of MitoVES in CII is particularly intriguing.
We found that the length of the aliphatic chain linking the tocopheryl
succinyl group and the TPP+ group of 11 carbons is optimal for
MitoVES, since its shortening by 2 carbons at a time causes gradual
loss of the activity of the agent, such that MitoVE7S and MitoVE5S
have a barely detectable ROS-and apoptosis-inducing activity [80,116].
Further, we found that MitoVES suppressed the two activities of CII
with different efﬁcacy: the SDH activity with IC50~70 μM and the SQR
activity with IC50~1.7 μM. This is a very important ﬁnding, since it
points to preferential inhibition by MitoVES of the SQR activity by way
of interfering with UbQ binding in the Qp site. At relatively low levels
of MitoVES, the SDH activity will be relatively high, allowing for
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and their mobilisation towards Qp. Due to displacement of UbQ with
MitoVES, however, electrons will not be intercepted by their natural ac-
ceptor and will react with molecular oxygen to form the
apoptosis-inducing superoxide [80,116] (Fig. 4C).
The clinical relevance ofMitoVES is documented by its highly efﬁcient
anti-cancer effect in twomodels of neoplastic disease: the transgenic FVB/
N c-neu mice with spontaneous HER2high breast carcinomas and nude
mice with colon cancer xenografts [80,116] (Fig. 5A,B). The agent was
more than 20-fold more efﬁcient than the untargeted α-TOS with only
marginal if any secondary toxicity, which is of considerable importance
for the translational potential of MitoVES. Interestingly, we observed
that themolecularmode of action of the agent uncovered in tissue culture
experiments is similar to that exerted by the agent in vivo, as documented
in Fig. 5C. In these experiments, we used HCT116 (colorectal) cells stably
transfected with the oxygen-dependent destruction (ODD) domain of
HIF1α, that controls its stability, fused with GFP. Treatment of the cells
withMitoVES for extended periods of time generated green ﬂuorescence,
presumably due to pseudohypoxia based on higher accumulation of suc-
cinate [62,78]. The same cells were used to form a tumour in nude
mice (c.f. Fig. 5B), and the treatment of the mice with MitoVES in-
duced development of green ﬂuorescence, as detected in tumour
sections (Fig. 5C).
We have found yet another intriguing effect of MitoVES. In Fig. 1,
MitoVES is also placed in Class 8 of mitocans, i.e. compounds that affect
mtDNA. The reason is that the agent at concentrations below those
needed to induce apoptosis, considerably suppresses the level ofmtDNA transcripts, in particular the D-LOOP transcript, affecting mito-
chondrial homeostasis and cancer cell proliferation (Truksa et al., sub-
mitted for publication). This was not observed for the untargeted
α-TOS. The fact that the effect on the D-LOOP transcript was gradually
lost with shortening the aliphatic chain of MitoVES indicates that in
this case, the effect of MitoVES on mtDNA may be, after all, mediated
by its initial interaction with CII, although this has to be resolved. In
any case, this is an interesting bioactivity of MitoVES that makes the
agent suppress cancer cell proliferation in an apoptosis-independent
manner. Collectively, the above data endow mitochondrially targeted
VE analogues, epitomised by MitoVES, with a great translational
potential.
4.3. 3-Bromopyruvate
3-Bromopyruvate (3BP) is an interesting compound acting via
several modes (Table 1, Fig. 1). It is a Class 1 mitocan, interfering
with hexokinase (HK) activity [119–121]. Its major effect on HK
stems from its being an alkylating agent, binding to HK2 and causing
its dissociation from the voltage-dependent anion channel (VDAC)
[122]. It is apparent that 3BP causes the death of cancer cells by
means of fast depletion of ATP,which translated into anti-tumour activity
in animalmodels [119,123]. 3BP is also an inhibitor of CII, interferingwith
the SDH activity [124], and we used 3BP to document that α-TOS does
not inhibit CII by preferential interaction with the SDHA subunit [26].
Notwithstanding the effect of 3BP on CII, its main target is considered
to be HK2. The clinical relevance of this compound is documented by
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Fig. 4. Mitochondrial localisation of MitoVES, its interaction with CII and the molecular mechanism of its effect on CII. A. Mouse breast cancer NeuTL cells were incubated with
MitoTracker Red and ﬂuorescently labelled MitoVES or α-TOS and inspected by confocal microscopy. Hoechst 33342 was used to visualise the nuclei. B. Molecular modelling indi-
cated the position of MitoVES at the interface of the MIM and matrix components of CII. C. MitoVES inhibits both SDH and SQR activity of CII, the former with IC50~70 μM, the latter
with IC50~2 μM. Due to this scenario, the conversion of succinate to fumarate occurs in the presence of MitoVES, albeit at a lower rate, generating electrons that are forced to trans-
verse to the membrane components of CII. In the situation when UbQ is displaced from the Qp site in CII, electrons lack their natural acceptor and recombine with molecular oxygen
to give rise to superoxide. This then triggers a series of reactions that result in the induction of the apoptotic cascade, resulting in the demise of the cell.
Adapted from [19,80,116].
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issue, a case studywas published inwhich 3BPwas successful to extend
the life of a ﬁbrolamellar hepatocellular carcinoma patient, indicating a
possible clinical application of the agent [126].
4.4. Malonate and 3-nitropropionic acid
Malonate and 3-nitropropionic acid (3NP) are compounds speciﬁ-
cally inhibiting the SDH activity of CII; this results in the generation of
ROS and induction of apoptosis [127,128]. Malonate is an importanttool when studying the contribution of individual complexes to respira-
tion of cells and tissues. 3NP has also been used in the elucidation of the
precise architecture of CII [34]. As anti-cancer agents, the two com-
pounds are of limited value due to their secondary toxicity, in particular
being neurotoxic as documented in experimental animals, where they
cause severe neurological disorders [129,130].
Hence, with regard to future anti-cancer drug development, the
UbQ-binding sites in the SDHC and SDHD subunits may prove to be
better suited targets than sites in the SDHA catalytic domain given
the associated problem of neurotoxicity. Inhibiting SDH activity also
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Adapted from [80] and [116].
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pool and hence, the metabolic TCA cycle arrest could have much
more serious consequences for the cell than the selective inhibition
of electron transfer involving the UbQ sites. In the latter case, the TCA
cycle would not become fully inhibited, but the disruption of the elec-
tron ﬂow at the UbQ sites would still allow for efﬁcient superoxide
formation.4.5. Thenoyltriﬂuoroacetone
While malonate and 3NP act at the level of the SDHA subunit of
CII, thenoyltriﬂuoroacetone (TTFA) interferes with the UbQ-binding
site between the SDHC and SDHD subunits. It was discovered in the
1960s as a compound that interferes with the oxidation of succinate
[131]. It was further found that TTFA affects the UbQ site in CII and SQR
560 K. Kluckova et al. / Biochimica et Biophysica Acta 1827 (2013) 552–564activity that causes reduction of UbQ to UbQH2 [132,133]. TTFA was
shown to induce apoptosis, cause generation of superoxide/hydrogen
peroxide and increase the Ca2+ levels [134]. The problem with clinical
use of TTFA is that it is highly toxic to non-cancerous cells such
as hepatocytes [135], in stark contrast to VE analogues [91]. Thus,
TTFA is used as a molecular tool to study the structure and function of
CII, and was useful in precise deﬁning the Qp site in the porcine CII
that was recently crystallised [34].
4.6. Troglitazone
Similarly as the anti-diabetic agentmetformin thatwas found to also
act onCI to induce ROS generation and apoptosis [136], the anti-diabetic
drugs from the group of thiazolidinedione compounds [137] represent-
ed by troglitazone were found to interfere with the activity of CII [138].
However, since troglitazone and several other thialidinediones have been
found to be highly toxic, including hepatotoxicity and cardiotoxicity, they
have been withdrawn [139,140], which limits their use as potential
anti-cancer agents.
4.7. Atpenins
An interesting group of agents acting via targeting CII are atpenins.
They were discovered some 25 years ago as fungal metabolites [141].
Soon after, one of the members of the group, atpenin B, was found to
considerably suppress ATP levels in the Raji B lymphoma cells [142].
Some 10 years later, it was found that atpenins, epitomised by
atpenin A5, act by interfering with the UbQ site in CII and prevent re-
duction of UbQ [143,144]. While a lot has been done in terms of un-
derstanding the molecular target for atpenins, not much is known
about their anti-cancer activity. Thus far there is only one paper
reporting on the inhibitory effect of synthetic atpenins on prostate
cancer cells [145]. A recent report describes that natural compounds,
including atpenins, can suppress the growth of prostate cancer cells
by targeting the prostate stromal cells via reducing the expression
of the insulin-like growth factor-I [146]. Of considerable interest are
ﬁndings that by targeting CII, atpenins protect non-malignant tissues,
such as the heart muscle, from the pathological effect of events like is-
chemic insult [147–149]. Very recently, atpenin A5 was used to better
understand the mechanism of ROS generation from CII [67]. This is an
important report, since it clearly documents that CII can contribute
to the formation of superoxide, which has biological and pathologi-
cal implications. Since more analogues of atpenins are being
synthesised, it is only a question of time when their effects on can-
cer cells and tumours will be tested and reported in the literature
[150–152].
5. Conclusions, further perspectives and clinical relevance
CII is a pharmacologically interesting target, given the possibility
to relatively independently interfere with its two enzymatic activi-
ties, the ‘main’ SDH activity which maintains the TCA cycle, and the
SQR activity, which supports the SDH activity by electron transfer to
UbQ. The inhibition of the former may be clinically problematic, due
to high level of side effects such as neurotoxicity, possible related to
high dependence of neurons on oxidative phosphorylation and TCA.
From our experience and from the literature, it appears that the SQR
activity may be a preferred target within CII that may be of clinical
relevance. Differences in afﬁnity (full blockade versus partial blockade
of SQR activity at intracellular concentrations) between indiscriminately
cytotoxic TTFA and cancer-speciﬁc VE analogues may perhaps explain
the different effects in non-cancerous cells. TTFAmay inhibit SQR too ef-
ﬁciently and thus compromise the SDH activity too much in all cells,
leading to the loss of speciﬁcity. In addition, unknown side effects and in-
discriminate uptake by various types of cells may also contribute to TTFA
toxicity. The speciﬁcity of VE analogues for cancer cells may be alsoco-determined by the following issues. First, the succinyl moiety of the
ester analogues is hydrolysed by esterases abundant in non-cancerous
cells. Second, they are increased levels of anti-oxidant defense systems
in normal cells. Finally, being weak acids, agents like α-TOS will be
more readily taken up by cancer cells due to the acidic nature of the tu-
mour interstitium.MitoVES then appears to derive its selectivity for can-
cer cells largely from the fact that it crosses the plasmamembrane on the
basis of the potential, which is higher in cancer cells than in normal
cells. It then speciﬁcally associates with mitochondria (spanning
the MIM/matrix interface) due to high MIM potential of cancer
cells. MitoVES has the optimum length of the aliphatic chain to
span the interface and reach and interfere with the Qp site of CII,
yet allowing SDH activity to proceed to some degree. The electrons,
however, cannot be all intercepted by UbQ and form the
apoptosis-inducing superoxide [80,116].
The eligibility of CII as a target for anti-cancer drugs is not
compromised by the occurrence of mutations in its subunits in cancers.
These mutations are associated with relatively infrequent and non-
aggressive familiar neoplasias such as paragangliomas and pheochromo-
cytomas, certain percentage of gastrointestinal stromal tumours and
pre-cancerous hamartomas in the Cowden syndrome [58,153–155].
Therefore, CII represents an invariant target in most cancers.
We have started with low scale clinical trials of α-TOS focusing on
the currently fatal mesotheliomas. To this end, a single mesothelioma
patientwas receiving trans-dermalα-TOS, which increased her survival
by several years. While we still not completely understand the reasons
for possible development of resistance to α-TOS, we found that in
cancer cells, their long-term exposure to the agent causes upregulation
of amember of the ABC family protein that renders the cells resistant to
the drug. We also found that this resistance is overcome by MitoVES
(Prochazka et al., submitted for publication). These ﬁndings provide
us with knowledge how to proceed in the planned clinical trials. If suc-
cessful, this will place CII at the pedestal of clinically relevant targets,
whose exploitation is at its very beginning but is already showing con-
siderable promise.Acknowledgements
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